Improved structural variant interpretation for hereditary cancer susceptibility using long-read sequencing.

genome sequencing hereditary cancer long-read sequencing structural variants variant interpretation

Journal

Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831

Informations de publication

Date de publication:
11 2020
Historique:
received: 07 01 2020
accepted: 15 06 2020
pubmed: 7 7 2020
medline: 29 4 2021
entrez: 7 7 2020
Statut: ppublish

Résumé

Structural variants (SVs) may be an underestimated cause of hereditary cancer syndromes given the current limitations of short-read next-generation sequencing. Here we investigated the utility of long-read sequencing in resolving germline SVs in cancer susceptibility genes detected through short-read genome sequencing. Known or suspected deleterious germline SVs were identified using Illumina genome sequencing across a cohort of 669 advanced cancer patients with paired tumor genome and transcriptome sequencing. Candidate SVs were subsequently assessed by Oxford Nanopore long-read sequencing. Nanopore sequencing confirmed eight simple pathogenic or likely pathogenic SVs, resolving three additional variants whose impact could not be fully elucidated through short-read sequencing. A recurrent sequencing artifact on chromosome 16p13 and one complex rearrangement on chromosome 5q35 were subsequently classified as likely benign, obviating the need for further clinical assessment. Variant configuration was further resolved in one case with a complex pathogenic rearrangement affecting TSC2. Our findings demonstrate that long-read sequencing can improve the validation, resolution, and classification of germline SVs. This has important implications for return of results, cascade carrier testing, cancer screening, and prophylactic interventions.

Identifiants

pubmed: 32624572
doi: 10.1038/s41436-020-0880-8
pii: S1098-3600(21)00772-3
pmc: PMC7605438
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1892-1897

Subventions

Organisme : CIHR
Pays : Canada

Références

Gibbs RA, et al. A global reference for human genetic variation. Nature. 2015;526:68–74.
Jain M, et al. Nanopore sequencing and assembly of a human genome with ultra-long reads. Nat Biotechnol. 2018;36:338–345.
pubmed: 5889714 pmcid: 5889714
Cheng DT, et al. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. BMC Med Genomics. 2017;10:33.
pubmed: 28526081 pmcid: 28526081
Sanchis-Juan A, et al. Complex structural variants in Mendelian disorders: identification and breakpoint resolution using short- and long-read genome sequencing. Genome Med. 2018;10:95.
pubmed: 30526634 pmcid: 30526634
Merker JD, et al. Long-read genome sequencing identifies causal structural variation in a Mendelian disease. Genet Med. 2018;20:159–163.
pubmed: 28640241 pmcid: 28640241
Jones MR, et al. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer. Ann Oncol. 2017;28:3092–3097.
pubmed: 28950338 pmcid: 28950338
Richards S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–423.
pubmed: 25741868 pmcid: 25741868
Wick RR, Judd LM, Holt KE. Performance of neural network basecalling tools for Oxford nanopore sequencing. Genome Biol. 2019;20:129.
pubmed: 31234903 pmcid: 31234903
Li H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics. 2018;34:3094–3100.
pubmed: 29750242 pmcid: 6137996
Sedlazeck FJ, et al. Accurate detection of complex structural variations using single-molecule sequencing. Nat Methods. 2018;15:461–468.
pubmed: 29713083 pmcid: 5990442
Zhao EY, et al. Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer. Clin Cancer Res. 2017;23:7521–7530.
pubmed: 29246904
Wong H-L, et al. Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing. Cold Spring Harb Mol Case Stud. 2018;4:a002329.
pubmed: 29092957 pmcid: 5793777
Carvalho CMB, Lupski JR. Mechanisms underlying structural variant formation in genomic disorders. Nat Rev Genet. 2016;17:224–238.
pubmed: 26924765 pmcid: 4827625
Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421.
pubmed: 23945592 pmcid: 23945592
Sudmant PH, et al. An integrated map of structural variation in 2,504 human genomes. Nature. 2015;526:75–81.
pubmed: 4617611 pmcid: 4617611
Rhees J, Arnold M, Boland CR. Inversion of exons 1-7 of the MSH2 gene is a frequent cause of unexplained Lynch syndrome in one local population. Fam Cancer. 2014;13:219–225.
pubmed: 24114314 pmcid: 3984383
Metcalfe KA, et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol. 2010;28:387–391.
pubmed: 20008623
Gilpatrick T, et al. Targeted nanopore sequencing with Cas9-guided adapter ligation. Nat Biotechnol. 2020;38:433–438.
pubmed: 32042167 pmcid: 32042167

Auteurs

My Linh Thibodeau (ML)

Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Hereditary Cancer Program, BC Cancer, Vancouver, BC, Canada.

Kieran O'Neill (K)

Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.

Katherine Dixon (K)

Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.

Caralyn Reisle (C)

Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.

Karen L Mungall (KL)

Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.

Martin Krzywinski (M)

Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.

Yaoqing Shen (Y)

Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.

Howard J Lim (HJ)

Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada.

Dean Cheng (D)

Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.

Kane Tse (K)

Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.

Tina Wong (T)

Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.

Eric Chuah (E)

Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.

Alexandra Fok (A)

Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Hereditary Cancer Program, BC Cancer, Vancouver, BC, Canada.

Sophie Sun (S)

Hereditary Cancer Program, BC Cancer, Vancouver, BC, Canada.
Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada.

Daniel Renouf (D)

Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada.

David F Schaeffer (DF)

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

Carol Cremin (C)

Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
Hereditary Cancer Program, BC Cancer, Vancouver, BC, Canada.

Stephen Chia (S)

Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada.

Sean Young (S)

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

Pawan Pandoh (P)

Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.

Stephen Pleasance (S)

Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.

Erin Pleasance (E)

Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.

Andrew J Mungall (AJ)

Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.

Richard Moore (R)

Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.

Stephen Yip (S)

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

Aly Karsan (A)

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

Janessa Laskin (J)

Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada.

Marco A Marra (MA)

Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.

Kasmintan A Schrader (KA)

Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada. ischrader@bccancer.bc.ca.
Hereditary Cancer Program, BC Cancer, Vancouver, BC, Canada. ischrader@bccancer.bc.ca.

Steven J M Jones (SJM)

Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada. sjones@bcgsc.ca.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH